Videos

Anthony Hunter, MD, presents the case of a 76-year-old woman with newly diagnosed primary myelofibrosis with a JAK2 mutation, for which he recommended treatment with momelotinib due to her moderate anemia and refusal of transplant.

Anthony Hunter, MD, presents the case of a 76-year-old woman with newly diagnosed primary myelofibrosis with a JAK2 mutation, for which he recommended treatment with momelotinib due to her moderate anemia and refusal of transplant.

Over the past decade, the frontline treatment landscape for metastatic melanoma has evolved with studies like CheckMate-067 and KEYNOTE-006 highlighting the superiority of PD-1-based therapies over ipilimumab, and recent trials introducing new combination treatments.

Rafael Fonseca, MD, discusses the sequencing of CAR-T and bispecific antibodies in patients with relapsed/refractory multiple myeloma and tailoring treatment based on prior medical history for elderly and frail individuals.

Dr Fonseca shares findings from the MonumenTAL-1 trial presented at ASCO 2023, suggesting potentially reduced infection rates in patients with relapsed/refractory multiple myeloma receiving talquetamab relative to BCMA-targeted agents.

Hussein Tawbi, MD, PhD, emphasizes that combination immunotherapies offer higher efficacy than single agent PD-1 inhibitors for metastatic melanoma; however, patient characteristics guide the choice of treatment regimen, with toxicities playing a key role.

Arlene O. Siefker-Radtke, MD, discusses the results of the phase 3 THOR study of erdafitinib vs pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations.

Following their program on data updates in GU cancer from ESMO 2023, Oncology Brothers Rahul Gosain, MD, and Rohit Gosain, MD, share key takeaways from SunRISe-1, EV-302, and PSMAfore.

Shared insight from Rana McKay, MD, and the Oncology Brothers on updated data from PSMAfore and the use of Lutetium-177–PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Shifting their focus to metastatic bladder cancer, the Oncology Brothers and Rana McKay, MD, reflect on data from EV-302 and consider how enfortumab vedotin + pembrolizumab has shifted the treatment landscape.

Key opinion leader Rana McKay, MD, joins the Oncology Brothers Rahul Gosain, MD, and Rohit Gosain, MD, to review updated data in GU cancer from ESMO 2023, starting with TAR-200 monotherapy in patients with NMIBC and the SunRISE-1 trial.

Bradley McGregor, MD, discusses the rationale behind the multi-institutional, prospective, single-arm phase 2 trial of cabozantinib, nivolumab, and ipilimumab for the treatment of patients with renal cell carcinoma with variant histologies.

Nirav Shah, MD, discusses long-term data from the phase 1/2 BRUIN study which evaluated pirtobrutinib in mantle cell lymphoma, and next steps for evaluating the agent.

Vijaya Raj Bhatt, MBBS, MS, discusses background and findings from a multicenter, phase 2 study of ruxolitinib for the treatment of patients with steroid refractory sclerotic chronic graft-versus-host disease.

Explores the intricate decision-making process for frontline treatment in BPDCN patients, with considerations for age, fitness, and various therapeutic approaches.

Expert insight into the diagnostic markers and challenges of BPDCN, including the importance of involving dermatologists and pathologists, to identify various disease presentations in both adult and pediatric patients.

Matthew Ulrickson, MD, discusses a patient case of BPDCN, emphasizing the importance of recognizing and treating this rare disease, exploring various treatment options, and highlighting the evolving prognosis.

Lucia Masarova, MD, PhD, discusses the rationale of the EXCEED-ET study of ropeginterferon alfa-2b-njf for patients with essential thrombocytopenia.

A discussion on streamlining patient care processes between urologists and medical oncologists while maintaining treatment continuity and minimizing disruptions for patients with prostate cancer.

Dr Rafael Fonesca reviews data from the TriMM-2 study presented at ASCO 2023 investigating combination talquetamab plus daratumumab for patients with relapsed/refractory multiple myeloma, highlighting a 78% response rate to talquetamab, but noting side effects like CRS and infections.

The RELATIVITY-047 trial evaluated relatlimab and nivolumab versus nivolumab alone in patients with metastatic melanoma, revealing improved progression-free survival, while PDL-1 status wasn't predictive of outcomes.

Experts share insights into collaborative relay strategies between urologists and medical oncologists that ensure smooth handoffs and continued care for patients with prostate cancer receiving combination therapies.

Hussein Tawbi, MD, PhD, explains that LAG-3 is a marker of T-cell exhaustion, and combining LAG-3 inhibitors with PD-1 inhibitors can reverse this exhaustion, enhancing T-cell effectiveness and showing therapeutic benefits in patients with metastatic melanoma.

Rafael Fonseca, MD, emphasizes the considerations of selecting therapies targeting specific markers like BCMA and GPRC5D in patients with relapsed/refractory multiple myeloma, such as prior exposures, efficacy, and potential side effects.

Explore the criteria for considering doublet or triplet therapies in advanced prostate cancer, examining their potential benefits and minimal added toxicity as discussed by key opinion leaders.

Hayder Saeed, MD, discusses how the mechanism of action of tafasitamab makes the therapy a potent cancer cell killer for patients with diffuse large B-cell lymphoma.

Tracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, reflect on how to incorporate sequencing and personalized treatments effectively in oncology practice.

Key opinion leaders explore the evolving landscape of precision medicine in gastrointestinal cancers and how molecular profiling is transforming treatment decisions for patients.

Joan Culpepper-Morgan, MD, provides an overview on different treatment approaches for patients with hepatocellular carcinoma.

Joshua K. Sabari, MD, discusses where research on LY3537982 for patients with KRAS G12C-mutant advanced solid tumors is headed.